SCI & TECH● LOWSep 11 · Sep 11, 2026, 12:59 PM
Exelixis zanzalintinib NDA review extended three months by FDA
Seeking Alpha Tech · north america
The FDA has extended its review period for Exelixis' zanzalintinib NDA by three months. This indicates a longer assessment timeframe for the new drug application.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH29m agoTowering glacial ice cliffs may collapse in fits and startsNew ScientistSCI & TECH29m agoGoogle showcases way to fix quantum computer errors more efficientlyNew ScientistSCI & TECH36m agoAnthropic grants employee-level access to nonprofit AI evaluator METRSeeking Alpha TechSCI & TECH37m agoExperts discuss roadmap for quantum-resistant digital infrastructureThe Hindu